Taken together, our data are promising for the establishment of new and more specific therapeutic strategies in MS that target CEACAM1 and thereby reduce the detrimental effects of B cell-mediated autoimmunity in the CNS. This evidence concerns the gene CEACAM1 and Autoimmunity.